涉案6.52亿元 步长制药子公司起诉知名跨国企业中国公司

Core Viewpoint - The company BuChang Pharmaceutical (603858.SH) has filed a lawsuit against Jiemai (Shanghai) Medical International Trade Co., Ltd. over a contract dispute involving an amount of 652 million yuan [2]. Group 1: Lawsuit Details - The lawsuit involves BuChang's subsidiary, Shanghai HePu Medical Technology Co., Ltd., which claims that Jiemai Shanghai failed to properly handle the transfer of inventory after their distribution agreement expired [3]. - Shanghai HePu is seeking the repurchase of approximately 556 million yuan worth of remaining inventory, a refund of 3.2078 million yuan in advance payments, and compensation for interest losses amounting to 92 million yuan, along with other legal costs [3]. - The case has been officially accepted by the court, but a hearing date has not yet been set [3]. Group 2: Inventory and Financial Implications - There is a risk associated with the 5.5 billion yuan inventory, which may require a provision for inventory impairment, potentially impacting the company's current and future profits [4]. - The lawsuit was filed after the court hearing took place on December 16, which was approximately two weeks prior to the public announcement by BuChang Pharmaceutical [4].